Drug Profile
House dust mite allergy vaccine - Stallergenes Greer plc
Alternative Names: Dust mite extract immunotherapy - Stallergenes Greer plc; HDM immunotherapy - Stallergenes Greer plc; House dust mite immunotherapy - Stallergenes Greer plcLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Greer Laboratories
- Developer Stallergenes Greer plc
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in USA (Sublingual, Drops)
- 17 Mar 2009 Efficacy and adverse events data from a phase I trial in Allergic rhinitis presented at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2009) ,
- 31 Dec 2005 Phase-I clinical trials in Allergic rhinitis in USA (Sublingual)